{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:59:51Z","timestamp":1784735991227,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":579,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.nrl.2013.10.004","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T10:44:32Z","timestamp":1387449872000},"page":"302-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Consenso espa\u00f1ol actualizado sobre el uso del natalizumab (Tysabri\u00ae)-2013"],"prefix":"10.1016","volume":"30","author":[{"given":"O.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Garc\u00eda-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"\u00c1lvarez-Cerme\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Olascoaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodr\u00edguez-Antig\u00fcedad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Meca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2013.10.004_bib0005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.nrl.2011.09.008","article-title":"Spanish consensus on the use of natalizumab (Tysabri\u00ae)--2011","volume":"27","author":"Fern\u00e1ndez","year":"2012","journal-title":"Neurologia"},{"key":"10.1016\/j.nrl.2013.10.004_bib0010","unstructured":"Ficha t\u00e9cnica de natalizumab 2013. Agencia Europea de Medicamentos [consultado 29 Sep 2013]. Disponible en: http:\/\/www.ema.europa.eu"},{"key":"10.1016\/j.nrl.2013.10.004_bib0015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study","volume":"259","author":"Fern\u00e1ndez","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2012.08.027","article-title":"Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis","volume":"323","author":"Prosperini","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrl.2013.10.004_bib0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0035","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2013.10.004_bib0040","series-title":"Presentado en el 23 congreso de la ENS","article-title":"Association between baseline factors and on-treatment disease activity and safety in natalizumab-treated patients with relapsing-remitting multiple sclerosis in the TYSABRI\u00ae (natalizumab) Observational Program","author":"Wiendl","year":"2013"},{"key":"10.1016\/j.nrl.2013.10.004_bib0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2013.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0060","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00415-011-6275-7","article-title":"Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS","volume":"259","author":"Weinstock-Guttman","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: Effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0070","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1352458511399611","article-title":"Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis","volume":"17","author":"Phillips","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0075","first-page":"321","article-title":"An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis","volume":"52","author":"Horga","year":"2011","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","article-title":"Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: Results from a multi-center study in German speaking countries","volume":"17","author":"Putzki","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","article-title":"Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study","volume":"31 Suppl 3","author":"Sangalli","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nrl.2013.10.004_bib0090","doi-asserted-by":"crossref","first-page":"e58643","DOI":"10.1371\/journal.pone.0058643","article-title":"Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting","volume":"8","author":"Svenningsson","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.nrl.2013.10.004_bib0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2011.03648.x","article-title":"Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response","volume":"19","author":"R\u00edo","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458511417481","article-title":"Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis","volume":"18","author":"Prosperini","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.P01.211","article-title":"Comparison of patients treated with natalizumab and interferon beta\/glatiramer using propensity-matched multiple sclerosis registry data (P01.211)","author":"Spelman","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0110","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0115","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0120","series-title":"Presentado en el 57 congreso de la SEFH","article-title":"Costes por brote evitado de natalizumab y fingolimod en el tratamiento de pacientes con EM","author":"Farf\u00e1n-Sedano","year":"2012"},{"key":"10.1016\/j.nrl.2013.10.004_bib0125","first-page":"S41","article-title":"Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies","volume":"19","author":"Owens","year":"2013","journal-title":"J Manag Care Pharm JMCP"},{"key":"10.1016\/j.nrl.2013.10.004_bib0130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3111\/13696998.2011.602444","article-title":"Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis","volume":"14","author":"O\u2019Day","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.nrl.2013.10.004_bib0135","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1185\/03007990902876040","article-title":"Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis","volume":"25","author":"Chiao","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nrl.2013.10.004_bib0140","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1352458510379819","article-title":"Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists","volume":"16","author":"Heesen","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0145","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients\u2019 benefit-risk preferences: serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0150","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1177\/1352458508095729","article-title":"Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis","volume":"14","author":"Thangarajh","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI22833","article-title":"Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS","volume":"115","author":"Villar","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nrl.2013.10.004_bib0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0295","doi-asserted-by":"crossref","first-page":"S30.001","DOI":"10.1212\/WNL.80.7_supplement.S30.001","article-title":"Longitudinal stability of anti-JC virus antibody status in multiple sclerosis patients: results of Stratify-1","volume":"80","author":"Plavina","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0175","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1352458510385508","article-title":"Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months","volume":"17","author":"Oliver","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0180","series-title":"Presentado en el congreso 65 de la AAN","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients: survival and functional outcome when asymptomatic at diagnosis","author":"Dong-Si","year":"2013"},{"key":"10.1016\/j.nrl.2013.10.004_bib0185","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0190","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O\u2019Connor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0195","series-title":"Presentado en el 28 congreso del ECTRIMS","article-title":"Long-term observation on management of natalizumab discontinuation","author":"Sangalli","year":"2012"},{"key":"10.1016\/j.nrl.2013.10.004_bib0200","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10875-011-9522-x","article-title":"Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism","volume":"31","author":"Ramos-Cejudo","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0205","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1212\/WNL.0b013e3182735d24","article-title":"Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod","volume":"79","author":"Gross","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0210","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1177\/1352458512454773","article-title":"Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: Report of six cases","volume":"18","author":"Hakiki","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","article-title":"Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment","volume":"69","author":"Havla","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0220","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: An observational study","volume":"128","author":"Sempere","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nrl.2013.10.004_bib0225","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: Clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0230","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-012-6808-8","article-title":"Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis","volume":"260","author":"Havla","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0235","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/1352458512468498","article-title":"Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption","volume":"19","author":"Laroni","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.10.004_bib0240","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","article-title":"Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring","volume":"6","author":"Kappos","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0245","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0250","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2013.10.004_bib0255","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0260","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0265","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","author":"Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2013.10.004_bib0300","series-title":"Presented at ENS","first-page":"O288","article-title":"Use of anti-JC virus antibody index to further define risk of PML in anti-JCV antibodies-positive natalizumab-treated patients with MS","author":"Plavina","year":"2013"},{"key":"10.1016\/j.nrl.2013.10.004_bib0275","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.10441","article-title":"Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis","volume":"53","author":"Villar","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2013.10.004_bib0280","series-title":"LXIV Reuni\u00f3n anual de la Sociedad Espa\u00f1ola de Neurolog\u00eda","article-title":"Las BOC de IgM se asocian con un menor riesgo de LMP en pacientes con EM tratados con natalizumab","author":"Villar","year":"2012"},{"key":"10.1016\/j.nrl.2013.10.004_bib0285","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2013.10.004_bib0290","series-title":"Presentado en el 28 congreso del ECTRIMS","article-title":"Five-year safety and efficacy data of natalizumab from the STRATA study","author":"Kappos","year":"2012"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485313002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485313002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T22:51:11Z","timestamp":1716331871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485313002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0213485313002430"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2013.10.004","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consenso espa\u00f1ol actualizado sobre el uso del natalizumab (Tysabri\u00ae)-2013","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2013.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}